Mesenchymal stromal cells: cell-based therapies for traumatic central nervous system injuries

² Department of Cell Processing and Transfusion, The Institute of Medical Science, The University of Tokyo,108-8639 Shirokanedai, Minato-Ku, Tokyo, Japan

^*Correspondence: takeo-m@ims.u-tokyo.ac.jp (Takeo Mukai)
Academic Editor: Masato Nakafuku

J. Integr. Neurosci. 2022, 21(2), 44; https://doi.org/10.31083/j.jin2102044

Submitted: 31 July 2021 | Revised: 11 August 2021 | Accepted: 24 August 2021 | Published: 18 March 2022

This is an open access article under the CC BY 4.0 license.

Abstract

Traumatic central nervous system (CNS) injury often causes irreversible impairment, and new alternative therapies for the treatment of CNS injury and sequelae are expected to be developed. Recently, mesenchymal stromal cells (MSCs) have started being used as cell therapy for neurological disorders such as traumatic CNS injury based on their immunomodulatory, neuroprotective, and neurorestorative abilities. Based on the premise of basic research, numerous clinical trials using MSCs for the treatment of traumatic CNS injury have been performed, and the feasibility and efficacy of this therapy have been reported. In this review we aimed to shed light on the characteristics of MSCs and to discuss the basic and clinical research and recent progress in clinical studies using MSCs to treat various traumatic neurological injuries.

Keywords

Mesenchymal stromal cell

Traumatic central nervous system injury

Neurological disorders

Umbilical cord

Neurotrophic factors

Figures

Fig. 1.

Previous article in this issue

Next article in this issue

J. Integr. Neurosci. Print ISSN 0219-6352 Electronic ISSN 1757-448X